VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ARDXArdelyx, Inc.
$6.37$1.6B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksARDXP/E History

ARDX logoArdelyx, Inc. (ARDX) P/E Ratio History

Deep Value

Trading at -24.5x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2015–2015

Current P/E (TTM)
-24.5x
-115% vs 5Y avg
5Y Avg P/E
166.9x
Median 166.9x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
TTM EPS$-0.24
Price$6.37
Earnings YieldN/A
EPS Growth (1Y)-52.9%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 23, 2026, Ardelyx, Inc. (ARDX) trades at a price-to-earnings ratio of -24.5x, with a stock price of $6.37 and trailing twelve-month earnings per share of $-0.24.

The current P/E is 115% below its 5-year average of 166.9x. Over the past five years, ARDX's P/E has ranged from a low of 166.9x to a high of 166.9x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, ARDX trades at a 211% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.

Relative to the broader market, ARDX trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARDX DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

ARDX Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-24.5vs22.1
-211%
Below Sector
vs. S&P 500
-24.5vs24.3
-201%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -53% EPS growth (1Y)

ARDX P/E vs Peers

Commercial Specialty Pharma peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
INVA logoINVAInnoviva, Inc.
$2B6.9Lowest0.66Best+817%Best
AMGN logoAMGNAmgen Inc.
$186B24.28.07+88%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

ARDX Historical P/E Data (2015–2015)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2015 Q2-$3.99$0.02166.9x+0%

Average P/E for displayed period: 166.9x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

11+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ARDX — Frequently Asked Questions

Quick answers to the most common questions about buying ARDX stock.

What is ARDX's P/E ratio?

Ardelyx, Inc. (ARDX) trailing twelve-month P/E ratio is -24.5x, based on TTM diluted EPS of $-0.24. The 5-year average P/E is 166.9x and the historical range spans 166.9x to 166.9x.

Is ARDX stock overvalued or undervalued?

ARDX trades at -24.5x P/E, below its 5-year average of 166.9x. At the 0th percentile of its historical range (166.9x–166.9x), the stock is priced at a discount to its own history.

Is ARDX stock expensive?

No, ARDX is not expensive on a historical basis. The current P/E of -24.5x is below the 5-year average of 166.9x and sits at the 0th percentile of its valuation range.

What is ARDX's historical P/E range?

Over the past 5 years, ARDX's P/E ratio has ranged from 166.9x to 166.9x, with a median of 166.9x and an average of 166.9x. The current P/E of -24.5x places the stock at the 0th percentile of this range. Full historical data spans 2015–2015.

How does ARDX's P/E compare to the S&P 500?

ARDX trades at -24.5x P/E versus the S&P 500 median of 24.3x. The 201% discount to the market suggests lower growth expectations or perceived higher risk.

How does ARDX's valuation compare to Healthcare peers?

Ardelyx, Inc. P/E of -24.5x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is ARDX's PEG ratio?

ARDX PEG ratio is N/A, based on a P/E of -24.5x and EPS growth of -52.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is ARDX's earnings yield?

ARDX earnings yield is N/A, the inverse of its -24.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

ARDX P/E Ratio History (2015–2015)

Quarterly valuation multiple from closing price and trailing EPS

Current166.9x
Period Avg166.9x
Range166.9x - 166.9x
Change+0%
1 quartersJun 30, 2015 - Jun 30, 2015